- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement | 8 | FiercePharma | ||
| Fr | Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. | 7 | Seeking Alpha | ||
| Fr | Teva Pharmaceutical Industries Ltd: Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea | 566 | GlobeNewswire (Europe) | According to the settlement agreement, the proposed biosimilar to Eylea (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances
REYKJAVIK... ► Artikel lesen | |
| Fr | Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea | 253 | GlobeNewswire (Europe) | REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of... ► Artikel lesen | |
| Mi | Hagens Berman Sobol Shapiro LLP: Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman | 92 | PR Newswire | SAN FRANCISCO, Dec. 17, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over... ► Artikel lesen | |
| Mi | Alvotech - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mi | Alvotech to raise $100M via convertible bonds, provides 2026 forecast | 6 | Seeking Alpha | ||
| ALVOTECH SDR Aktie jetzt für 0€ handeln | |||||
| Mi | Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering | 153 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| Di | Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance | 232 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 24.11. | Alvotech's AVT03 approved by European Commission as biosimilar to Prolia and Xgeva | 6 | Seeking Alpha | ||
| 24.11. | European Commission approves Alvotech's biosimilar denosumab | 4 | Investing.com | ||
| 24.11. | Europäische Kommission erteilt Alvotech Zulassung für Denosumab-Biosimilar | 6 | Investing.com Deutsch | ||
| 24.11. | Alvotech Announces Approval of AVT03, a Biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area | 270 | GlobeNewswire (Europe) | REYKJAVIK, Iceland, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| 21.11. | Alvotech and Advanz announce EC approval for Gobivaz biosimilar | 4 | Pharmaceutical Technology | ||
| 20.11. | Alvotech - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.11. | Alvotech, Advanz Pharma secure European approval for Gobivaz, Simponi biosimilar | 3 | Seeking Alpha | ||
| 20.11. | European Commission approves Alvotech's biosimilar golimumab | 7 | Investing.com | ||
| 20.11. | Alvotech S.A.: Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) | 1.107 | GlobeNewswire (Europe) | Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ("Advanz Pharma"), a... ► Artikel lesen | |
| 20.11. | XFRA NEW INSTRUMENTS AVAILABLE ON 20.11.2025 | 265 | Xetra Newsboard | The following instruments on XETRA do have their first trading 20.11.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.11.2025
Aktien
1 SE0025011463 Alvotech SDR
2 AU0000004DS8... ► Artikel lesen | |
| 12.11. | Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update | 577 | GlobeNewswire (Europe) | Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine... ► Artikel lesen |
1 2 3 4 5 Weiter >>
126 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 18,520 | +2,83 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | ||
| DYNE THERAPEUTICS | 19,850 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | +0,73 % | Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock | ||
| SUMMIT THERAPEUTICS | 17,820 | +4,52 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| IMMUNEERING | 5,650 | -0,35 % | Immuneering Corporation: Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | - End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA - - Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 -... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,400 | +3,32 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 4,360 | -3,11 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| QIAGEN | 38,740 | +0,77 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,010 | +6,73 % | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | ||
| VIR BIOTECHNOLOGY | 5,760 | -2,87 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | +0,26 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ABSCI | 3,380 | -0,88 % | Absci Partners With Oracle And AMD To Accelerate AI-Driven Drug Discovery | SUNNYVALE (dpa-AFX) - Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD)... ► Artikel lesen | |
| VOR BIOPHARMA | 12,410 | -3,05 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| ARVINAS | 11,680 | +3,55 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen |
Das Unternehmen ALVOTECH SDR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,260 (-6,13 %) liegt der Kurs bei 3,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALVOTECH SDR finden Sie auf Wallstreet Online.